Phathom Pharmaceuticals Reports Strong Q4 & FY25 Results, Guides for 2026 Profitability, and Strengthens Capital Structure
PHAT has more than doubled off its 52-week low of $2.21.
Summary
Phathom Pharmaceuticals announced robust Q4 and full-year 2025 financial results, including significant revenue growth and reduced net losses, while providing positive 2026 guidance projecting operating profitability and cash flow positivity in 2027, bolstered by a recent $130 million equity offering and debt restructuring.
Key Events · Earnings and Guidance · PHAT
-
Strong 2025 Financial Performance
Reported Q4 2025 net revenues of $57.6 million and full-year 2025 net revenues of $175.1 million, a 217% increase from 2024. Net loss significantly improved to $21.1 million in Q4 2025 from $74.5 million in Q4 2024.
-
Positive 2026 Financial Guidance
Projected 2026 net revenues of $320–$345 million and anticipates achieving operating profitability beginning in Q3 2026 and for the full year, with cash flow positivity expected in 2027.
-
Strengthened Capital Structure
Completed a $130 million equity offering in January 2026 (net proceeds $122.2 million) and modified its term debt facility in February 2026, reducing principal to $175 million, lowering interest, and extending maturity to February 2029. The company now holds approximately $190 million in cash.
-
VOQUEZNA Commercial Progress
Reported over 1.1 million total VOQUEZNA prescriptions filled to date, with a 24% increase in Q4 2025 prescriptions quarter-over-quarter. The sales force realignment was completed, operating at over 95% strength.
Analysis · PHAT · Life Sciences
Phathom Pharmaceuticals delivered robust financial results for Q4 and full-year 2025, showcasing significant revenue growth and a substantial reduction in net losses. The company's net revenues for 2025 increased by 217% year-over-year, demonstrating strong commercial progress for VOQUEZNA. Crucially, Phathom provided positive 2026 financial guidance, projecting operating profitability to begin in Q3 2026 and for the full year, with cash flow positivity anticipated in 2027. This positive outlook is further bolstered by the successful completion of a $130 million equity offering in January 2026 and a strategic modification of its term debt facility in February 2026, which reduced outstanding principal, lowered interest rates, and extended maturity. These actions have significantly strengthened the company's financial position, providing approximately $190 million in cash on hand and a clear runway to achieve its profitability goals, mitigating near-term liquidity concerns.
At the time of this filing, PHAT was trading at $13.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $964.6M. The 52-week trading range was $2.21 to $18.31. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.